Literature DB >> 7909677

Calcium channel blocking drug overdose: an Australian series.

D M Howarth1, A H Dawson, A J Smith, N Buckley, I M Whyte.   

Abstract

1. A descriptive case study of calcium channel-blocking drug (CCB) overdoses in the Hunter Region of NSW was performed to analyse the in-hospital morbidity and mortality of CCB drug overdoses in an Australian population. 2. The patients were admitted to major hospitals within the Hunter Region and treated initially with gastrointestinal decontamination, including the use of oral activated charcoal. Further management was required in most cases and included intravenous calcium, atropine and inotropic support. 3. Of the 15 CCB overdoses, four patients died. Noncardiogenic pulmonary oedema occurred in two other cases. Cardiac conduction defects occurred in 11 cases. 4. Atropine was found to be effective only after intravenous calcium had been administered. 5. Overdose with slow-release verapamil required prolonged treatment with intravenous calcium salts. 6. Overdose with verapamil or diltiazem in doses greater than 300 mg carries a significant risk of death and potentially life threatening arrhythmias occur with lower doses. 7. Recommended initial management includes early, effective gastrointestinal decontamination. High dose intravenous calcium salts should be given to reverse hypotension and bradycardia. Atropine and inotropic support are frequently required.

Entities:  

Mesh:

Substances:

Year:  1994        PMID: 7909677     DOI: 10.1177/096032719401300304

Source DB:  PubMed          Journal:  Hum Exp Toxicol        ISSN: 0960-3271            Impact factor:   2.903


  11 in total

1.  Life-threatening calcium channel blocker overdose and its management.

Authors:  Imran Rizvi; Ajaz Ahmad; Ankush Gupta; Shamsuz Zaman
Journal:  BMJ Case Rep       Date:  2012-05-30

Review 2.  Calcium channel antagonist and beta-blocker overdose: antidotes and adjunct therapies.

Authors:  Andis Graudins; Hwee Min Lee; Dino Druda
Journal:  Br J Clin Pharmacol       Date:  2015-10-30       Impact factor: 4.335

Review 3.  Amlodipine fatality in an infant with postmortem blood levels.

Authors:  Henry A Spiller; Beth A Milliner; George M Bosse
Journal:  J Med Toxicol       Date:  2012-06

4.  A risk assessment based approach to the management of acute poisoning.

Authors:  F F S Daly; M Little; L Murray
Journal:  Emerg Med J       Date:  2006-05       Impact factor: 2.740

5.  Overdose with calcium channel blockers.

Authors:  N A Buckley; I M Whyte; A H Dawson
Journal:  BMJ       Date:  1994-06-18

Review 6.  Management of calcium channel antagonist overdose.

Authors:  Steven D Salhanick; Michael W Shannon
Journal:  Drug Saf       Date:  2003       Impact factor: 5.606

Review 7.  Controlled release drugs in overdose. Clinical considerations.

Authors:  N A Buckley; A H Dawson; D A Reith
Journal:  Drug Saf       Date:  1995-01       Impact factor: 5.606

8.  Experts Consensus Recommendations for the Management of Calcium Channel Blocker Poisoning in Adults.

Authors:  Maude St-Onge; Kurt Anseeuw; Frank Lee Cantrell; Ian C Gilchrist; Philippe Hantson; Benoit Bailey; Valéry Lavergne; Sophie Gosselin; William Kerns; Martin Laliberté; Eric J Lavonas; David N Juurlink; John Muscedere; Chen-Chang Yang; Tasnim Sinuff; Michael Rieder; Bruno Mégarbane
Journal:  Crit Care Med       Date:  2017-03       Impact factor: 7.598

Review 9.  [Cardiac arrest under special circumstances].

Authors:  Carsten Lott; Anatolij Truhlář; Anette Alfonzo; Alessandro Barelli; Violeta González-Salvado; Jochen Hinkelbein; Jerry P Nolan; Peter Paal; Gavin D Perkins; Karl-Christian Thies; Joyce Yeung; David A Zideman; Jasmeet Soar
Journal:  Notf Rett Med       Date:  2021-06-10       Impact factor: 0.826

Review 10.  Treatment for calcium channel blocker poisoning: a systematic review.

Authors:  M St-Onge; P-A Dubé; S Gosselin; C Guimont; J Godwin; P M Archambault; J-M Chauny; A J Frenette; M Darveau; N Le Sage; J Poitras; J Provencher; D N Juurlink; R Blais
Journal:  Clin Toxicol (Phila)       Date:  2014-10-06       Impact factor: 4.467

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.